Handelsavisen
prelaunch
Companies ›Healthcare ›EIFG.DE
EI
EIFG.DE — XETRA Healthcare Facilities & Services

MedNation AG

€3,76
Open in Charts → Attach watcher ⌖
— —
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
2,8 %
ROE
0,9 %
Net margin
0,2 %
Debt / equity
1,06
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Business description not yet wired for this issuer.

Business. EIFG.DE is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals. The firm generates revenue through service-based models typical of the healthcare services sector. It is headquartered in Germany and is primarily listed on the Xetra exchange under the ticker EIFG.DE. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
0,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EIFG.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EIFG.DE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    EIFG.DE is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals. The firm generates revenue through service-based models typical of the healthcare services sector. It is headquartered in Germany and is primarily listed on the Xetra exchange under the ticker EIFG.DE. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company operates in the healthcare sector, providing pharmaceutical products and related services, generating revenue primarily through the sale of its pharmaceutical offerings.

    The company is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a high confidence level of 0.92 based on verified market data.

    The company maintains a debt-to-equity ratio of 1.06, indicating a moderate level of leverage, while its current ratio of 1.57 suggests it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity concerns.

    In terms of profitability, the company's return on equity is 0.009 and return on assets is 0.0029, both of which are below the industry median for the Healthcare Facilities & Services sector. This suggests that the company is underperforming relative to its peers in terms of generating returns for shareholders and utilizing its assets efficiently.

    The company's revenue is primarily concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.

    Looking ahead, the company is projected to experience a modest growth trajectory, with revenue expected to increase in the next fiscal year. However, the exact numeric deltas for this growth have not been disclosed in the available data.

    The company faces several risk factors, including medium liquidity risk and a negative net cash position after subtracting total debt. While the potential for dilution is currently low, the company's financial structure and capital needs could change in the future, affecting shareholder value.

    Recent events, such as filings and transcripts, have not been disclosed in the available data, making it difficult to assess any recent developments that may impact the company's performance or strategy.

    - The company has a moderate level of leverage with a debt-to-equity ratio of 1.06. - Return on equity and return on assets are below the industry median, indicating underperformance. - Revenue is concentrated in a single segment, increasing exposure to market fluctuations. - The company is projected to experience modest growth in the next fiscal year. - Liquidity risk is medium, with a negative net cash position after subtracting total debt.

    Key takeaways
    • EIFG.DE is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals.
    • The firm generates revenue through service-based models typical of the healthcare services sector.
    • It is headquartered in Germany and is primarily listed on the Xetra exchange under the ticker EIFG.DE.
    • Specific details regarding operating segments and geographic revenue mix are not available.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €3,76
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    €11.6M
    Net cashⓘ
    -€9.4M
    Current ratioⓘ
    1.6
    Debt / equityⓘ
    1.1
    ROAⓘ
    0.3%
    ROEⓘ
    0.9%
    Cash conversionⓘ
    2210.0%
    CapEx / revenueⓘ
    -1.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin2,8 %Below median
    Net Margin0,2 %Below median
    ROE0,9 %Below median
    Capex / Rev-1,8 %Above P75
    D/E1,06Bottom quartile
    Cash Conv22,10Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • EIFG.DE Market data — financials · 2026-05-27
    • MedNation AG Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Joerg Karsten LeueChairman of the Supervisory Board
    • Lothar LotzkatMember of the Management Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EIFG.DECanonical
    XETRA · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage